Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. Background: PHA-848125 (PHA) is a dual CDK/TRKA oral inhibitor showing ...
A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. This is an ASCO Meeting Abstract from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results